Astonea Labs Share Price & Earnings Call Analysis
- Market cap
- ₹347 Cr
- P/E
- 76.73
- ROE
- 11.97%
- PEG
- 0.79
- Price to sales
- 2.35
- Debt to equity
- 0.75
- 52W high / low
- ₹369 / ₹118
- EBITDA margin
- 9.15%
- Net profit margin
- 3.06%
- Promoter holding
- 72.44%
- Sales (last year)
- ₹148 Cr
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Astonea Labs.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Astonea Labs
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Astonea Labs
Quarterly Results
Quarter-by-quarter operating performance
Financials of Astonea Labs
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Sales + | 30.04 | 66.89 | 80.06 | 97.38 |
| Expenses + | 24.21 | 59.75 | 68.14 | 82.09 |
| Operating Profit | 5.83 | 7.14 | 11.92 | 15.29 |
| OPM % | 19.41% | 10.67% | 14.89% | 15.70% |
| Other Income + | 0.12 | 0.21 | 0.10 | 0.19 |
| Interest | 1.58 | 2.34 | 2.97 | 3.83 |
| Depreciation | 3.79 | 3.93 | 3.67 | 4.58 |
| Profit before tax | 0.58 | 1.08 | 5.38 | 7.07 |
| Tax % | 56.90% | 38.89% | 24.35% | 24.33% |
| Net Profit + | 0.25 | 0.67 | 4.07 | 5.35 |
| EPS in Rs | 0.62 | 1.68 | 5.36 | 6.93 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Astonea Labs
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 7.60 | 7.72 | 10.51 |
| Reserves | 3.49 | 4.16 | 4.26 | 10.69 | 42.96 |
| Borrowings + | 29.53 | 35.99 | 42.39 | 53.33 | 39.05 |
| Other Liabilities + | 15.89 | 20.13 | 26.47 | 31.64 | 29.30 |
| Total Liabilities | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
| Fixed Assets + | 21.39 | 20.75 | 21.75 | 25.03 | 26.08 |
| CWIP | 0.00 | 0.00 | 2.10 | 5.01 | 6.27 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 31.52 | 43.53 | 56.87 | 73.34 | 89.47 |
| Total Assets | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
Financials of Astonea Labs
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -4.93 | -1.05 | 7.86 | 9.25 |
| Cash from Investing Activity + | -3.31 | -3.08 | -8.35 | -11.14 |
| Cash from Financing Activity + | 8.17 | 4.14 | -0.26 | 1.62 |
| Net Cash Flow | -0.07 | 0.01 | -0.75 | -0.27 |
| Free Cash Flow | -8.26 | -4.17 | 0.42 | -1.51 |
| CFO/OP | -75% | -9% | 71% | 70% |
Financials of Astonea Labs
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 234.63 | 104.11 | 115.94 | 141.91 |
| Inventory Days | 136.35 | 121.40 | 160.81 | 160.68 |
| Days Payable | 273.08 | 128.11 | 148.90 | 143.66 |
| Cash Conversion Cycle | 97.89 | 97.41 | 127.85 | 158.93 |
| Working Capital Days | 98.30 | 32.79 | 28.22 | 29.31 |
| ROCE % | 8.01% | 16.97% | 17.30% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.